117078-41-8

Basic information

• Product Name: Carbamimidic acid, N-cyano-N'-[4-[3-(1-piperidinylmethyl)phenoxy]butyl]-, phenyl ester
• CAS NO: 117078-41-8
• Molecular Formula: C24H30N4O2
• Molecular Weight: 406.528
• Mol File: 117078-41-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Carbamimidic acid, N-cyano-N'-[4-[3-(1-piperidinylmethyl)phenoxy]butyl]-, phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamimidic acid, N-cyano-N'-[4-[3-(1-piperidinylmethyl)phenoxy]butyl]-, phenyl ester(117078-41-8)
• EPA Substance Registry System: Carbamimidic acid, N-cyano-N'-[4-[3-(1-piperidinylmethyl)phenoxy]butyl]-, phenyl ester(117078-41-8)

Safety Data

• Hazardous Substances Data: 117078-41-8(Hazardous Substances Data)

Upstream product

• 73279-05-7 4-[3-(1-Piperidinylmethyl)phenoxy]butanamine 
• 79463-77-7 N-cyanodiphenylcarbonimidate 

Downstream Products

• 1600520-48-6 N-cyano-N'-[4-[N-[(2-(4-fluorobenzyl)-N-(2-pyridyl)amino)ethyl]-N-methylamino]butyl]-N''-[3-[4-(4-(piperidin-1-yl)methyl)phenoxy]butyl]guanidine 
• 149841-15-6 N-[2-[N-[3-(4-chlorophenyl)-3-(2-pyridyl)propyl]-N-methylamino]ethyl]-N'-cyano-N-[4-[3-(piperidinomethyl)phenoxy]butyl]guanidine 
• 140873-22-9 C₂₇H₃₆N₁₀O₃ 
• 140873-54-7 C₃₃H₄₇N₇O₄ 
• 140873-20-7 C₂₆H₃₄N₁₀O₃ 
• 140873-42-3 C₂₈H₃₇N₉O₂ 
• 140873-36-5 C₂₇H₃₅N₉O₂ 
• 140873-39-8 C₂₇H₃₅I₂N₇O₂ 
• 140873-34-3 C₂₇H₃₅N₇O₄ 
• 140873-65-0 C₂₇H₃₈N₆O₃S 
• 140873-64-9 N-(2-benzenesulfonamidoethyl)-N'-cyano-N''-<4-<3-(1-piperidinylmethyl)phenoxy>butyl>guanidine 
• 140873-21-8 C₂₇H₃₇N₇O₃ 
• 140873-38-7 C₂₇H₃₆IN₇O₂ 
• 140873-19-4 N-cyano-N'-<2-(2-nitrophenylamino)ethyl>-N''-<4-<3-(1-piperidinylmethyl)phenoxy>butyl>guanidine 

Relevant articles and documents

Synthesis and dual histamine H1 and H2 receptor antagonist activity of cyanoguanidine derivatives

Premedication with a combination of histamine H1 receptor (H1R) and H2 receptor (H2R) antagonists has been suggested as a prophylactic principle, for instance, in anaesthesia and surgery. Aiming at pharmacological hybrids combining H1R and H2R antagonistic activity, a series of cyanoguanidines 14-35 was synthesized by linking mepyramine-type H1R antagonist substructures with roxatidine-, tiotidine-, or ranitidine-type H2R antagonist moieties. N-desmethylmepyramine was connected via a poly-methylene spacer to a cyanoguanidine group as the "urea equivalent" of the H2R antagonist moiety. The title compounds were screened for histamine antagonistic activity at the isolated ileum (H1R) and the isolated spontaneously beating right atrium (H2R) of the guinea pig. The results indicate that, depending on the nature of the H2R antagonist partial structure, the highest H1R antagonist potency resided in roxatidine-type compounds with spacers of six methylene groups in length (compound 21), and tiotidine-type compounds irrespective of the alkyl chain length (compounds 28, 32, 33), N-cyano-N'-[2-[[(2- guanidino-4-thiazolyl)methyl] thio]ethyl]-N″-[2-[N-[2-[N-(4-methoxybenzyl)-N-(pyridyl)-amino] ethyl]-N-methylamino]ethyl] guanidine (25, pKB values: 8.05 (H1R, ileum) and 7.73 (H2R, atrium) and the homologue with the mepyramine moiety connected by a six-membered chain to the tiotidine-like partial structure (compound 32, pKB values: 8.61 (H1R) and 6.61 (H2R) were among the most potent hybrid compounds. With respect to the development of a potential pharmacotherapeutic agent, structural optimization seems possible through selection of other H1R and H2R pharmacophoric moieties with mutually affinity-enhancing properties.

H2-Antihistaminics. 39. Basic substituted aryloxyalkylguanidine derivatives and analogs with H2-antagonistic action

-